person · Reporting owner
Kowalsky Matthew Paul
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INCENTA · Entity 5673 | Chief Legal Officer | February 12, 2026 | February 13, 2026 |
| Protara Therapeutics, Inc.PRTO · Entity 6203 | VP, Legal and Secretary | January 18, 2019 | January 23, 2019 |
| Sigilon Therapeutics, Inc.SGTX · Entity 11481 | CHIEF OF STAFF AND CLO | August 11, 2023 | August 11, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ENANTA PHARMACEUTICALS INC
Report date February 12, 2026 · Filed February 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,591 |
Ending reported balance
After 2026-02-12 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-02-12 · Grant · Acquired 1,318 · Balance 1,318 F1: Represents shares of Enanta common stock issued under performance share units ("PSUs") that vested as a result of performance against two-year research and development milestones in the calendar 2024-2025 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2026. Row 2 · 2026-02-12 · Grant · Acquired 4,175 · Balance 5,493 F2: Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over the same 60-day calendar periods two years apart. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2026. Row 3 · 2026-02-12 · Tax withholding · Disposed 1,902 · Balance 3,591 F3: Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of Enanta common stock issued under performance share units ("PSUs") that vested as a result of performance against two-year research and development milestones in the calendar 2024-2025 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2026.
F2: Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over the same 60-day calendar periods two years apart. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2026.
F3: Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards.
Protara Therapeutics, Inc.
Report date January 18, 2019 · Filed January 23, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.64 · Expires 2029-01-17 | Direct | 60,000 |
Reported balance
After 2019-01-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-01-18 · Grant · Acquired 60,000 · Balance 60,000 F1: The options were granted on January 18, 2019 and the shares underlying this option vest 25% on the first anniversary of the grant date and the remaining shares vest in twelve equal quarterly installments. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted on January 18, 2019 and the shares underlying this option vest 25% on the first anniversary of the grant date and the remaining shares vest in twelve equal quarterly installments.
Sigilon Therapeutics, Inc.
Report date August 11, 2023 · Filed August 11, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 1
1 source rowRow 1 · 2023-08-11 · Disposition to issuer · Disposed 1,925 · Balance 0 F1: Pursuant to the Merger Agreement, as of the Effective Time, these shares were converted into the right to receive consideration per share of (i) $14.92, net to the stockholder in cash, without interest plus (ii) one Contingent Value Right ("CVR") per share. F2: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split F3: Includes 412 shares acquired by the Reporting Person pursuant to the Issuer's 2020 Employee Stock Purchase Plan ("ESPP") for the purchase periods from October 3, 2022 to August 3, 2023. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock. These transaction are exempt under Rule 16b-3(c). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.17 · Expires 2033-02-27 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-08-11 · Disposition to issuer · Disposed 12,690 · Balance 0 F2: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split F4: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one CVR per Share subject to such stock option immediately prior to the Acceptance Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Merger Agreement, as of the Effective Time, these shares were converted into the right to receive consideration per share of (i) $14.92, net to the stockholder in cash, without interest plus (ii) one Contingent Value Right ("CVR") per share.
F2: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split
F3: Includes 412 shares acquired by the Reporting Person pursuant to the Issuer's 2020 Employee Stock Purchase Plan ("ESPP") for the purchase periods from October 3, 2022 to August 3, 2023. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock. These transaction are exempt under Rule 16b-3(c).
F4: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one CVR per Share subject to such stock option immediately prior to the Acceptance Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 12, 2026 Filed Feb 13, 2026 21:33 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Tax withholdingCommon Stock | 1,902 | $14.25 | $27,103.50 |
DisclosureSEC source: 0002064832-26-000016 · form4.xml · nonDerivative · entry 3 Kowalsky Matthew Paul · CIK 0001705824 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,591 F3 · shares: Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards. Read SEC document |
| February 12, 2026 Filed Feb 13, 2026 21:33 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantCommon Stock | 4,175 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000016 · form4.xml · nonDerivative · entry 2 Kowalsky Matthew Paul · CIK 0001705824 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,493 F2 · shares: Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over the same 60-day calendar periods two years apart. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2026. Read SEC document |
| February 12, 2026 Filed Feb 13, 2026 21:33 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantCommon Stock | 1,318 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000016 · form4.xml · nonDerivative · entry 1 Kowalsky Matthew Paul · CIK 0001705824 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,318 F1 · shares: Represents shares of Enanta common stock issued under performance share units ("PSUs") that vested as a result of performance against two-year research and development milestones in the calendar 2024-2025 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2026. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:08 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantStock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $13.66 | $0.00 |
DisclosureSEC source: 0002064832-25-000030 · form4.xml · derivative · entry 1 Kowalsky Matthew Paul · CIK 0001705824 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2035-11-25 F1 · derivative.exercise_date: Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 25, 2025). Read SEC document |
| November 27, 2024 Filed Nov 27, 2024 22:10 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $8.83 | $0.00 |
DisclosureSEC source: 0001062993-24-019776 · form4.xml · derivative · entry 1 Kowalsky Matthew Paul · CIK 0001705824 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2034-11-27 F1 · derivative.exercise_date: Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 27, 2024). Read SEC document |
| April 29, 2024 Filed May 1, 2024 20:27 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $13.25 | $0.00 |
DisclosureSEC source: 0001062993-24-009175 · form4.xml · derivative · entry 1 Kowalsky Matthew Paul · CIK 0001705824 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2034-04-29 F1 · derivative.exercise_date: Twenty-five percent (25%) of such option will become exercisable on April 29, 2025 (the "Anniversary Date"), with the remainder to become exercisable quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over three years from the Anniversary Date (in each case subject to the optionholder's continued employment). Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 16:10 UTC | Sigilon Therapeutics, Inc. SGTX · Entity 11481 | Disposition to issuerStock Option (Right to Buy) · Derivative | 12,690 | $0.75 Strike: $14.17 | $9,517.50 |
DisclosureSEC source: 0001415889-23-012133 · form4-08112023_040815.xml · derivative · entry 2 Kowalsky Matthew Paul · CIK 0001705824 · CHIEF OF STAFF AND CLO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,690 shares Expires 2033-02-27 F2 · derivative.exercise_price: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split F4 · price: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one CVR per Share subject to such stock option immediately prior to the Acceptance Time. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one CVR per Share subject to such stock option immediately prior to the Acceptance Time. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 16:10 UTC | Sigilon Therapeutics, Inc. SGTX · Entity 11481 | Disposition to issuerCommon Stock | 1,925 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-012133 · form4-08112023_040815.xml · nonDerivative · entry 1 Kowalsky Matthew Paul · CIK 0001705824 · CHIEF OF STAFF AND CLO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the Merger Agreement, as of the Effective Time, these shares were converted into the right to receive consideration per share of (i) $14.92, net to the stockholder in cash, without interest plus (ii) one Contingent Value Right ("CVR") per share. F2 · shares: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split F3 · shares: Includes 412 shares acquired by the Reporting Person pursuant to the Issuer's 2020 Employee Stock Purchase Plan ("ESPP") for the purchase periods from October 3, 2022 to August 3, 2023. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock. These transaction are exempt under Rule 16b-3(c). F1 · price: Pursuant to the Merger Agreement, as of the Effective Time, these shares were converted into the right to receive consideration per share of (i) $14.92, net to the stockholder in cash, without interest plus (ii) one Contingent Value Right ("CVR") per share. Read SEC document |
| February 28, 2023 Filed Mar 1, 2023 16:46 UTC | Sigilon Therapeutics, Inc. SGTX · Entity 11481 | GrantStock Option (Right to Buy) · Derivative | 165,000 | $0.00 Strike: $1.09 | $0.00 |
DisclosureSEC source: 0001415889-23-003686 · form4-03012023_090301.xml · derivative · entry 1 Kowalsky Matthew Paul · CIK 0001705824 · CHIEF OF STAFF AND CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,000 Underlying: Common Stock · 165,000 shares Expires 2033-02-27 F1 · derivative.exercise_date: The options vest as to 25% of the underlying shares of common stock on February 28, 2024, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each quarter following such date until the options are fully vested. Read SEC document |
| January 18, 2019 Filed Jan 23, 2019 21:19 UTC | Protara Therapeutics, Inc. PRTO · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001171843-19-000438 · ownership.xml · derivative · entry 1 Kowalsky Matthew Paul · CIK 0001705824 · VP, Legal and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock, $0.001 par value · 60,000 shares Expires 2029-01-17 F1 · derivative.exercise_date: The options were granted on January 18, 2019 and the shares underlying this option vest 25% on the first anniversary of the grant date and the remaining shares vest in twelve equal quarterly installments. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 13:19 UTC | Protara Therapeutics, Inc. PRTO · Entity 6203 | GrantCommon Stock | 2,448 | $1.93 | $4,724.64 |
DisclosureSEC source: 0001171843-19-000065 · ownership.xml · nonDerivative · entry 1 Kowalsky Matthew Paul · CIK 0001705824 · VP, Legal and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,479 F1 · kind: The shares were acquired under the Issuer's 2014 Employee Stock Purchase Plan for the plan period of July 1, 2018 through December 31, 2018 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 12:20 UTC | Protara Therapeutics, Inc. PRTO · Entity 6203 | GrantCommon Stock | 10,000 | $1.62 | $16,150.00 |
DisclosureSEC source: 0001171843-18-004990 · ownership.xml · nonDerivative · entry 1 Kowalsky Matthew Paul · CIK 0001705824 · VP, Legal and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,031 F1 · kind: The shares were acquired under the Issuer's 2014 Employee Stock Purchase Plan for the plan period of January 1, 2018 through June 30, 2018 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| January 17, 2018 Filed Jan 18, 2018 22:17 UTC | Protara Therapeutics, Inc. PRTO · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 110,000 | $0.00 Strike: $2.85 | $0.00 |
DisclosureSEC source: 0001171843-18-000443 · f4_011818kowalsky.xml · derivative · entry 1 Kowalsky Matthew Paul · CIK 0001705824 · VP, Legal and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock, $0.001 par value · 110,000 shares Expires 2028-01-16 F1 · derivative.exercise_date: The options were granted on January 17, 2018 and the shares underlying this option vest 25% on the first anniversary of the grant date and the remaining shares vest in twelve equal quarterly installments. Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 13:16 UTC | Protara Therapeutics, Inc. PRTO · Entity 6203 | GrantCommon Stock | 3,934 | $1.30 | $5,098.46 |
DisclosureSEC source: 0001171843-18-000083 · form4kowalsky.xml · nonDerivative · entry 1 Kowalsky Matthew Paul · CIK 0001705824 · VP, Legal and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,031 F1 · kind: The shares were acquired under the Issuer's 2014 Employee Stock Purchase Plan for the plan period of July 1, 2017 through December 31, 2017 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 20:11 UTC | Protara Therapeutics, Inc. PRTO · Entity 6203 | GrantCommon Stock | 10,000 | $1.30 | $12,960.00 |
DisclosureSEC source: 0001171843-17-003953 · formfour.xml · nonDerivative · entry 1 Kowalsky Matthew Paul · CIK 0001705824 · VP, Legal and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,097 F1 · kind: The shares were acquired under the Issuer's 2014 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.